SSY Group's Finerenone drug receives China registration approval

SSY Group Limited announced today that its drug Finerenone has received registration approval from the National Medical Products Administration of China. This approval allows Finerenone to be a bulk drug for preparations on the market, marking the second such approval for the group's entities in the People's Republic of China.

Finerenone is primarily utilized for adult patients suffering from chronic kidney disease associated with type 2 diabetes. Its key benefits include reducing the risks of sustained decline in estimated glomerular filtration rate (eGFR), preventing end-stage renal disease, and decreasing cardiovascular death and hospitalization due to heart failure.

This voluntary announcement aims to keep shareholders and potential investors updated on the latest business developments within SSY Group. The board of directors, as of this announcement dated December 5, 2025, includes Mr. Qu Jiguang, Mr. Su Xuejun, Mr. Meng Guo, Mr. Chow Hing Yeung, and Ms. Qu Wanrong as executive directors, with Mr. Liu Wenjun as a non-executive director, and Mr. Wang Yibing, Mr. Chow Kwok Wai, and Mr. Jiang Guangce serving as independent non-executive directors.